In clinical studies, GLP-1 analogues reduced stroke and myocardial infarction in high-risk patients with diabetes [11], reduced cardiovascular events in diabetic patients with a previous myocardial infarction [12], decreased hospitalization in heart failure patients [13], improved diastolic function in diabetic patients [14], and reduced physical limitation symptoms and hospitalization in patients with heart failure with preserved ejection fraction and obesity [15]. Here, GCG is linked to heart failure.